"The
Report Insomnia - Japan Drug Forecast and Market Analysis to 2023
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Insomnia
is the most common sleep disorder and is believed to affect
approximately 35% of the global population. The condition can be
defined as patient-reported difficultly with sleep initiation or
sleep maintenance which can include frequent awakenings, difficulty
returning to sleep after awakenings, or awakening too early with
inability to return to sleep. Cases of insomnia can be classified on
the basis of etiology into primary and secondary (or comorbid)
subtypes. The insomnia market is widely genericized creating a
competitive environment for new products. As such, the treatment
algorithm centers on the generically available nonbenzodiazepines and
low-dose sedating antidepressants, despite the launch of numerous
novel agents. The value of the insomnia market is set to further
decline following the loss of exclusivity for Sunovion/Dainippon
Sumitomos Lunesta, the top selling insomnia drug, in April 2014.
However, GlobalData expects the launch of two pipeline products from
a novel class of drugs to provide growth in the insomnia market as
they may address some of the unmet need.
GlobalData
estimates the drug sales for insomnia in 2013 were approximately
$380.4m in Japan. Aside from some year-to-year fluctuation, the value
of the insomnia market in Japan is expected to follow a growth trend
over the 10-year forecast period, reaching $432.4m by 2023. This
growth can be attributed to the launch of the orexin receptor
antagonists Belsomra and E-2006, and the continued uptake of Lunesta
and Rozerem prior to their respective patent expiries.
Get
the Free Sample copy of this Report @
http://www.marketresearchreports.biz/sample/sample/841031
Scope
- Overview of Insomnia
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2013-2023.
- Analysis of the impact of key
events as well the drivers and restraints affecting Japan Insomnia
market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Insomnia.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in Japan.
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
Table
of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 10
3.1 Etiology and
Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 16
3.2 Classification 17
3.3 Symptoms 20
3.4 Prognosis 20
4 Disease Management 22
4.1 Diagnosis and Treatment
Overview 22
4.1.1 Clinical Evaluation 22
4.1.2 Referral 26
4.1.3 Treatment Guidelines and
Leading Prescribed Drugs 26
4.1.4 Clinical Practice 28
4.2 Japan 32
5 Competitive Assessment 35
5.1 Overview 35
5.2 Product Profiles - Major
Brands 37
5.2.1 Nonbenzodiazepines 37
5.2.2 Benzodiazepines 76
5.2.3 Melatonin Receptor
Agonists 81
5.2.4 Low-Dose Sedating
Antidepressants 100
5.2.5 Orexin Receptor
Antagonists 113
5.3 Other Therapeutic Classes
124
6 Unmet Need and Opportunity
125
6.1 Overview 125
6.2 Novel Drugs with Improved
Safety Profiles 126
6.2.1 Unmet Need 126
6.2.2 Gap Analysis 128
6.2.3 Opportunity 129
6.3 Drugs That Can Be Used for
Long-Term Treatment 129
6.3.1 Unmet Need 129
6.3.2 Gap Analysis 130
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment